methimazole,
Phase 3Small molecule
methimazole, is one of 14 small molecule programs targeting Graves disease. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Graves Disease
#DrugCompanyPhaseTrials
1Tapazole
VViking Therapeutics, Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Synthroid
IInstitut Jerome Lejeune
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Efgartigimod PH20 SC
ArgenxPhase 3
Felzartamab
BiogenPhase 2
IMVT-1402
IImmunovant Sciences GmbH
Phase 2
BHV-1300
BBiohaven Therapeutics Ltd.
Phase 3
methimazole,
TThe First Affiliated Hospital of Xiamen University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for methimazole,. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details